Galapagos (NASDAQ:GLPG) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a report issued on Tuesday morning.

Several other analysts have also commented on the company. Sanford C. Bernstein assumed coverage on Galapagos in a report on Wednesday, November 26th. They set a “hold” rating for the company. Leerink Partners set a $40.00 target price on Galapagos and gave the company an “outperform” rating in a research report on Tuesday, October 21st. Royal Bank Of Canada raised their price target on Galapagos from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d)” rating on shares of Galapagos in a report on Wednesday, October 8th. Finally, Leerink Partnrs raised shares of Galapagos from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Galapagos has an average rating of “Reduce” and a consensus target price of $31.33.

Galapagos Trading Down 1.5%

NASDAQ GLPG opened at $32.61 on Tuesday. Galapagos has a 52 week low of $22.36 and a 52 week high of $37.78. The company has a 50 day moving average price of $31.61 and a 200 day moving average price of $31.78.

Institutional Investors Weigh In On Galapagos

A number of large investors have recently bought and sold shares of GLPG. XTX Topco Ltd purchased a new position in shares of Galapagos during the second quarter worth $1,114,000. 683 Capital Management LLC grew its position in Galapagos by 57.3% during the 1st quarter. 683 Capital Management LLC now owns 110,100 shares of the biotechnology company’s stock worth $2,766,000 after purchasing an additional 40,100 shares during the period. Vestal Point Capital LP raised its stake in shares of Galapagos by 11.1% during the 1st quarter. Vestal Point Capital LP now owns 200,000 shares of the biotechnology company’s stock valued at $5,024,000 after buying an additional 20,000 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Galapagos in the 2nd quarter valued at about $261,000. Finally, EcoR1 Capital LLC boosted its stake in shares of Galapagos by 569.0% in the second quarter. EcoR1 Capital LLC now owns 1,036,945 shares of the biotechnology company’s stock worth $29,024,000 after buying an additional 881,939 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

About Galapagos

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.